II
Therapeutic Areas
Tonix Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TNX-102 SL | Acute Stress Disorder (ASD) | Phase 2 |
| TNX-1500 | Organ Transplant Rejection / Autoimmune Disorders | Phase 1 |
| TNX-2900 | Prader-Willi Syndrome (PWS) | Phase 2 Ready |
| TNX-1900 | Migraine and Craniofacial Pain | Phase 1 |
| TNX-4800 | Prevention of Lyme Disease | Phase 1 |
| TNX-801 | Prevention of Mpox or Smallpox | Preclinical |
| TNX-1700 | Gastric and Colorectal Cancer | Preclinical |
| TNX-4200 | Not Specified (Target: CD45) | Preclinical |
Leadership Team at Tonix Pharmaceuticals
SL
Seth Lederman
Co-Founder, CEO & Chairman
GS
Gregory Sullivan
Chief Medical Officer
BS
Bradley Saenger
Chief Financial Officer
JE
Jessica Edgar Morris
Chief Operating Officer
SF
Siobhan Fogarty
Chief Technical Officer
SB
Sina Bavari
EVP, Infectious Disease R&D
BD
Bruce Daugherty
EVP, Research
TE
Thomas Englese
EVP, Commercial Operations
DR
Darryl Rideout
EVP, Experimental Chemistry
ZR
Zeil Rosenberg
EVP, Medical